Lynda Foltz

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Haifa Kathrin Al‐Ali, Philipp le Coutre, Cornelius F. Waller et al. · Haematologica · 2016 · 155 citations · Full text

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey

Claire Harrison, Steffen Koschmieder, Lynda Foltz et al. · Annals of Hematology · 2017 · 130 citations · Full text

Hematological Malignancy, Thrombosis, Polycythemia Vera +14

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Haifa Kathrin Al‐Ali, Martin Grießhammer, Lynda Foltz et al. · British Journal of Haematology · 2020 · 105 citations · Full text

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

John Mascarenhas, Moshe Talpaz, Vikas Gupta et al. · Haematologica · 2016 · 102 citations · Full text